160 related articles for article (PubMed ID: 17582475)
1. Overexpression of folate binding protein is associated with shortened progression-free survival in uterine adenocarcinomas.
Allard JE; Risinger JI; Morrison C; Young G; Rose GS; Fowler J; Berchuck A; Maxwell GL
Gynecol Oncol; 2007 Oct; 107(1):52-7. PubMed ID: 17582475
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of E-cadherin protein expression in pathological stage I-III endometrial cancer.
Mell LK; Meyer JJ; Tretiakova M; Khramtsov A; Gong C; Yamada SD; Montag AG; Mundt AJ
Clin Cancer Res; 2004 Aug; 10(16):5546-53. PubMed ID: 15328195
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of folate binding protein and mesothelin are associated with uterine serous carcinoma.
Dainty LA; Risinger JI; Morrison C; Chandramouli GV; Bidus MA; Zahn C; Rose GS; Fowler J; Berchuck A; Maxwell GL
Gynecol Oncol; 2007 Jun; 105(3):563-70. PubMed ID: 17400285
[TBL] [Abstract][Full Text] [Related]
4. Expression status of folate receptor alpha is significantly correlated with prognosis in non-small-cell lung cancers.
Iwakiri S; Sonobe M; Nagai S; Hirata T; Wada H; Miyahara R
Ann Surg Oncol; 2008 Mar; 15(3):889-99. PubMed ID: 18181001
[TBL] [Abstract][Full Text] [Related]
5. p53 protein overexpression: a strong prognostic factor in uterine papillary serous carcinoma.
Bancher-Todesca D; Gitsch G; Williams KE; Kohlberger P; Neunteufel W; Obermair A; Heinze G; Breitenecker G; Hacker NF
Gynecol Oncol; 1998 Oct; 71(1):59-63. PubMed ID: 9784320
[TBL] [Abstract][Full Text] [Related]
6. HER-2 is an independent prognostic factor in endometrial cancer: association with outcome in a large cohort of surgically staged patients.
Morrison C; Zanagnolo V; Ramirez N; Cohn DE; Kelbick N; Copeland L; Maxwell GL; Fowler JM
J Clin Oncol; 2006 May; 24(15):2376-85. PubMed ID: 16710036
[TBL] [Abstract][Full Text] [Related]
7. 14-3-3sigma in endometrial cancer--a possible prognostic marker in early-stage cancer.
Ito K; Suzuki T; Akahira J; Sakuma M; Saitou S; Okamoto S; Niikura H; Okamura K; Yaegashi N; Sasano H; Inoue S
Clin Cancer Res; 2005 Oct; 11(20):7384-91. PubMed ID: 16243811
[TBL] [Abstract][Full Text] [Related]
8. A multicenter evaluation of sequential multimodality therapy and clinical outcome for the treatment of advanced endometrial cancer.
Secord AA; Havrilesky LJ; O'Malley DM; Bae-Jump V; Fleming ND; Broadwater G; Cohn DE; Gehrig PA
Gynecol Oncol; 2009 Sep; 114(3):442-7. PubMed ID: 19560193
[TBL] [Abstract][Full Text] [Related]
9. Role of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) for prognosis in endometrial cancer.
Steiner E; Pollow K; Hasenclever D; Schormann W; Hermes M; Schmidt M; Puhl A; Brulport M; Bauer A; Petry IB; Koelbl H; Hengstler JG
Gynecol Oncol; 2008 Mar; 108(3):569-76. PubMed ID: 18222533
[TBL] [Abstract][Full Text] [Related]
10. The prognostic significance of the triple negative phenotype in endometrial cancer.
Kothari R; Morrison C; Richardson D; Seward S; O'Malley D; Copeland L; Fowler J; Cohn DE
Gynecol Oncol; 2010 Aug; 118(2):172-5. PubMed ID: 20605625
[TBL] [Abstract][Full Text] [Related]
11. Leptin expression correlates with favorable clinicopathologic phenotype and better prognosis in colorectal adenocarcinoma.
Paik SS; Jang SM; Jang KS; Lee KH; Choi D; Jang SJ
Ann Surg Oncol; 2009 Feb; 16(2):297-303. PubMed ID: 19050975
[TBL] [Abstract][Full Text] [Related]
12. Expression of estrogen receptor-alpha and -beta and progesterone receptor-A and -B in a large cohort of patients with endometrioid endometrial cancer.
Jongen V; Briët J; de Jong R; ten Hoor K; Boezen M; van der Zee A; Nijman H; Hollema H
Gynecol Oncol; 2009 Mar; 112(3):537-42. PubMed ID: 19108875
[TBL] [Abstract][Full Text] [Related]
13. Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial.
Benedetti Panici P; Basile S; Maneschi F; Alberto Lissoni A; Signorelli M; Scambia G; Angioli R; Tateo S; Mangili G; Katsaros D; Garozzo G; Campagnutta E; Donadello N; Greggi S; Melpignano M; Raspagliesi F; Ragni N; Cormio G; Grassi R; Franchi M; Giannarelli D; Fossati R; Torri V; Amoroso M; Crocè C; Mangioni C
J Natl Cancer Inst; 2008 Dec; 100(23):1707-16. PubMed ID: 19033573
[TBL] [Abstract][Full Text] [Related]
14. Uterine malignant mixed mullerian tumors should not be included in studies of endometrial carcinoma.
Vaidya AP; Horowitz NS; Oliva E; Halpern EF; Duska LR
Gynecol Oncol; 2006 Nov; 103(2):684-7. PubMed ID: 16797683
[TBL] [Abstract][Full Text] [Related]
15. p53 is correlated with low BMI negative progesterone receptor status and recurring disease in patients with endometrial cancer.
Seeger A; Kölbl H; Petry IB; Gebhard S; Battista MJ; Böhm D; Steiner E
Gynecol Oncol; 2012 Apr; 125(1):200-7. PubMed ID: 22210468
[TBL] [Abstract][Full Text] [Related]
16. Radiation-associated endometrial cancers are prognostically unfavorable tumors: a clinicopathologic comparison with 527 sporadic endometrial cancers.
Pothuri B; Ramondetta L; Eifel P; Deavers MT; Wilton A; Alektiar K; Barakat R; Soslow RA
Gynecol Oncol; 2006 Dec; 103(3):948-51. PubMed ID: 16870239
[TBL] [Abstract][Full Text] [Related]
17. Replicative MCM7 protein as a proliferation marker in endometrial carcinoma: a tissue microarray and clinicopathological analysis.
Li SS; Xue WC; Khoo US; Ngan HY; Chan KY; Tam IY; Chiu PM; Ip PP; Tam KF; Cheung AN
Histopathology; 2005 Mar; 46(3):307-13. PubMed ID: 15720416
[TBL] [Abstract][Full Text] [Related]
18. Endometrioid epithelial ovarian cancer : 20 years of prospectively collected data from a single center.
Storey DJ; Rush R; Stewart M; Rye T; Al-Nafussi A; Williams AR; Smyth JF; Gabra H
Cancer; 2008 May; 112(10):2211-20. PubMed ID: 18344211
[TBL] [Abstract][Full Text] [Related]
19. Stage IVB endometrial cancer: does applying an ovarian cancer treatment paradigm result in similar outcomes? A case-control analysis.
Landrum LM; Moore KN; Myers TK; Lanneau GS; McMeekin DS; Walker JL; Gold MA
Gynecol Oncol; 2009 Feb; 112(2):337-41. PubMed ID: 19041126
[TBL] [Abstract][Full Text] [Related]
20. Expression of the folate receptor genes FOLR1 and FOLR3 differentiates ovarian carcinoma from breast carcinoma and malignant mesothelioma in serous effusions.
Yuan Y; Nymoen DA; Dong HP; Bjørang O; Shih IeM; Low PS; Trope' CG; Davidson B
Hum Pathol; 2009 Oct; 40(10):1453-60. PubMed ID: 19454358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]